中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
13期
14-16
,共3页
朱莉莉%刘磊%李玉梅%李玉%陈勐%刘博%秦丹丹%李桂兰%郑岩
硃莉莉%劉磊%李玉梅%李玉%陳勐%劉博%秦丹丹%李桂蘭%鄭巖
주리리%류뢰%리옥매%리옥%진맹%류박%진단단%리계란%정암
肺疾病,慢性阻塞性%转化生长因子β1%参芎葡萄糖注射液
肺疾病,慢性阻塞性%轉化生長因子β1%參芎葡萄糖註射液
폐질병,만성조새성%전화생장인자β1%삼궁포도당주사액
Pulmonary disease,chronic obstructive%Transforming growth factor beta1%Shenxiong glucose injection
目的 评价参芎葡萄糖注射液对中、重度慢性阻塞性肺疾病(COPD)患者气道中转化生长因子β1(TGF-β1)的影响.方法 将64例中、重度COPD患者按随机数字表法分为参芎葡萄糖组(42例)和对照组(22例),两组均给予COPD的常规治疗,参芎葡萄糖组加用参芎葡萄糖注射液,对照组加用5％葡萄糖注射液,其治疗3个疗程.采用酶联免疫吸附法测定两组治疗前及每个疗程治疗后痰中TGF-β1.结果 参芎葡萄糖组和对照组治疗前痰中TGF-β1比较差异无统计学意义[(95.4±8.1)μg/L比(94.8±7.5)μg/L,P＞0.05].治疗第1个疗程后,参芎葡萄糖组痰中TGF-β1[(85.5±5.2) μg/L]较治疗前有所下降,但差异无统计学意义(P＞0.05);治疗第2,3个疗程后,参芎葡萄糖组痰中TGF-β1较治疗前显著下降[(61.5±5.8)、(49.1±4.5) μg/L],且显著低于同期对照组[(89.6±6.2)、(91.2±6.2)μg/L],差异有统计学意义(P＜0.05).对照组治疗第1,2,3个疗程后痰中TGF-β1与治疗前比较差异无统计学意义(P＞0.05).参芎葡萄糖组治疗过程中未发现明显药物不良反应(包括肝肾功能异常).结论 参芎葡萄糖注射液一定疗程后可显著降低中、重度COPD患者气道中TGF-β1表达,可能会减轻气道重塑反应.
目的 評價參芎葡萄糖註射液對中、重度慢性阻塞性肺疾病(COPD)患者氣道中轉化生長因子β1(TGF-β1)的影響.方法 將64例中、重度COPD患者按隨機數字錶法分為參芎葡萄糖組(42例)和對照組(22例),兩組均給予COPD的常規治療,參芎葡萄糖組加用參芎葡萄糖註射液,對照組加用5％葡萄糖註射液,其治療3箇療程.採用酶聯免疫吸附法測定兩組治療前及每箇療程治療後痰中TGF-β1.結果 參芎葡萄糖組和對照組治療前痰中TGF-β1比較差異無統計學意義[(95.4±8.1)μg/L比(94.8±7.5)μg/L,P＞0.05].治療第1箇療程後,參芎葡萄糖組痰中TGF-β1[(85.5±5.2) μg/L]較治療前有所下降,但差異無統計學意義(P＞0.05);治療第2,3箇療程後,參芎葡萄糖組痰中TGF-β1較治療前顯著下降[(61.5±5.8)、(49.1±4.5) μg/L],且顯著低于同期對照組[(89.6±6.2)、(91.2±6.2)μg/L],差異有統計學意義(P＜0.05).對照組治療第1,2,3箇療程後痰中TGF-β1與治療前比較差異無統計學意義(P＞0.05).參芎葡萄糖組治療過程中未髮現明顯藥物不良反應(包括肝腎功能異常).結論 參芎葡萄糖註射液一定療程後可顯著降低中、重度COPD患者氣道中TGF-β1錶達,可能會減輕氣道重塑反應.
목적 평개삼궁포도당주사액대중、중도만성조새성폐질병(COPD)환자기도중전화생장인자β1(TGF-β1)적영향.방법 장64례중、중도COPD환자안수궤수자표법분위삼궁포도당조(42례)화대조조(22례),량조균급여COPD적상규치료,삼궁포도당조가용삼궁포도당주사액,대조조가용5％포도당주사액,기치료3개료정.채용매련면역흡부법측정량조치료전급매개료정치료후담중TGF-β1.결과 삼궁포도당조화대조조치료전담중TGF-β1비교차이무통계학의의[(95.4±8.1)μg/L비(94.8±7.5)μg/L,P＞0.05].치료제1개료정후,삼궁포도당조담중TGF-β1[(85.5±5.2) μg/L]교치료전유소하강,단차이무통계학의의(P＞0.05);치료제2,3개료정후,삼궁포도당조담중TGF-β1교치료전현저하강[(61.5±5.8)、(49.1±4.5) μg/L],차현저저우동기대조조[(89.6±6.2)、(91.2±6.2)μg/L],차이유통계학의의(P＜0.05).대조조치료제1,2,3개료정후담중TGF-β1여치료전비교차이무통계학의의(P＞0.05).삼궁포도당조치료과정중미발현명현약물불량반응(포괄간신공능이상).결론 삼궁포도당주사액일정료정후가현저강저중、중도COPD환자기도중TGF-β1표체,가능회감경기도중소반응.
Objective To investigate the effect of Shenxiong glucose injection on transforming growth factor-β1 (TGF-β1) in airway of middle and serious chronic obstructive pulmonary disease (COPD).Methods A total of 64 patients with middle and serious COPD were divided into Shenxiong glucose group (42 cases) and control group (22 cases) by random digits table method.Conventional therapy of COPD was given in two groups.The patients in Shenxiong glucose group were treated by Shenxiong glucose injection and the patients in control group were treated by 5 percent glucose injection for 3 courses.TGF-β1 was measured before treatment and after each course in two groups by enzyme linked immunosorbent assay.Results There was no significant difference in TGF-β1 level of phlegm before treatment between two groups [(95.4 ± 8.1)μg/L vs.(94.8 ± 7.5) μg/L,P ＞ 0.05].TGF-β1 level of phlegm was decreased after 1 course [(85.5 ± 5.2)μg/L] compared with that before treatment in Shenxiong glucose group,but there was no significant difference (P ＞ 0.05).TGF-β1 level of phlegm was decreased after 2,3 courses [(61.5 ± 5.8),(49.1 ± 4.5)μg/L] compared with that before treatment,which was lower than that in control group [(89.6 ± 6.2),(91.2 ±6.2) μg/L],and there was significant difference (P＜ 0.05).There was no significant difference in TGF-β1 level of phlegm after 1,2,3 courses in control group,compared with that before treatment (P ＞0.05).The adverse reaction (including liver and kidney dysfunction) was not found in Shenxiong glucose group.Conclusion Shenxiong glucose injection has significant effect on TGF-β1 level of phlegm in patients with COPD at certain courses,and improve airway remodeling in patients with COPD at certain courses.
